TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its holdings in shares of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) by 0.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 846,884 shares of the company’s stock after selling 6,779 shares during the period. Vanguard Group Inc. owned 0.36% of TFF Pharmaceuticals worth $296,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. State Street Corp increased its holdings in shares of TFF Pharmaceuticals by 8.1% in the 1st quarter. State Street Corp now owns 69,929 shares of the company’s stock worth $441,000 after acquiring an additional 5,251 shares during the period. UBS Group AG increased its holdings in shares of TFF Pharmaceuticals by 12.3% in the 2nd quarter. UBS Group AG now owns 92,177 shares of the company’s stock worth $521,000 after acquiring an additional 10,123 shares during the period. Two Sigma Investments LP acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter worth about $60,000. Renaissance Technologies LLC acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter worth about $76,000. Finally, Millennium Management LLC acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter worth about $200,000. Institutional investors and hedge funds own 15.25% of the company’s stock.

TFF Pharmaceuticals Stock Down 8.6 %

Shares of TFFP opened at $3.52 on Tuesday. TFF Pharmaceuticals, Inc. has a 52-week low of $3.49 and a 52-week high of $21.25. The firm has a 50-day moving average price of $6.56 and a 200 day moving average price of $6.96. The firm has a market capitalization of $8.87 million, a PE ratio of -0.28 and a beta of 1.29.

Analyst Upgrades and Downgrades

Separately, Roth Mkm dropped their price objective on shares of TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, March 28th.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.